These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20819796)

  • 1. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
    Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
    Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
    Zacay G; Levy Y
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
    Isomura Y; Shirai Y; Kuwana M
    Rheumatology (Oxford); 2022 Nov; 61(11):4491-4496. PubMed ID: 35258561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Sakkas LI
    Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
    Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
    Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
    Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
    J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
    Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
    Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
    Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
    J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
    Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
    Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.
    Kuster S; Jordan S; Elhai M; Held U; Steigmiller K; Bruni C; Cacciapaglia F; Vettori S; Siegert E; Rednic S; Codullo V; Airo P; Braun-Moscovici Y; Hunzelmann N; Joao Salvador M; Riccieri V; Gheorghiu AM; Alegre Sancho JJ; Romanowska-Prochnicka K; Castellví I; Kötter I; Truchetet ME; López-Longo FJ; Novikov PI; Giollo A; Shirai Y; Belloli L; Zanatta E; Hachulla E; Smith V; Denton C; Ionescu RM; Schmeiser T; Distler JHW; Gabrielli A; Hoffmann-Vold AM; Kuwana M; Allanore Y; Distler O;
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Hagihara K; Shima Y; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Rheumatology (Oxford); 2010 Apr; 49(4):824-6. PubMed ID: 20008092
    [No Abstract]   [Full Text] [Related]  

  • 19. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.